Friday, 23 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
CompanyDigital

Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases

April 21, 2026
CompanyDrug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

April 21, 2026
CompanyDrug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

April 21, 2026
LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
CompanyDrug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

April 20, 2026
Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
CompanyDrug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

April 20, 2026
CompanyDeals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

April 20, 2026
CompanyDrug

Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 – 47.1% ORR and 14.0-Month PFS in Solid Tumors

April 20, 2026
Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium
CompanyDeals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

April 20, 2026
Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn's Disease Following February Approval
CompanyDrug

Eli Lilly Launches Omvoh (Mirikizumab) in China for Inflammatory Bowel Disease – IL-23p19 Antagonist Targets Ulcerative Colitis and Crohn’s Disease Following February Approval

April 20, 2026
SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners
CompanyDeals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

April 20, 2026
CompanyDrug

Kanghong Pharmaceutical Receives FDA Clearance for KHN921 Gene Therapy Trial in MYBPC3-Associated Hypertrophic Cardiomyopathy – Precision AAV Vector Targets Myocardial Tissue

April 20, 2026
Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation
CompanyDeals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

April 20, 2026
1 2 … 9 10 11 12 13 … 26 27
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up